These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

871 related items for PubMed ID: 16604728

  • 1. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators.
    Circulation; 2008 Oct 14; 118(16):1643-50. PubMed ID: 18824643
    [Abstract] [Full Text] [Related]

  • 4. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 14; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 5. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
    N Engl J Med; 1999 Sep 02; 341(10):709-17. PubMed ID: 10471456
    [Abstract] [Full Text] [Related]

  • 6. [Effect of spironolactone on mortality in patients with severe left ventricular dysfunction after acute myocardial infarction].
    Ruta J, Ptaszyński P, Maciejewski M, Chizyński K, Goch JH.
    Przegl Lek; 2006 Sep 02; 63(12):1249-51. PubMed ID: 17642132
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
    N Engl J Med; 2003 Apr 03; 348(14):1309-21. PubMed ID: 12668699
    [Abstract] [Full Text] [Related]

  • 8. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J, Ertl G.
    Med Klin (Munich); 2006 Jun 15; 101(6):458-66. PubMed ID: 16767569
    [Abstract] [Full Text] [Related]

  • 9. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Jun 15; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 10. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS.
    Am J Cardiovasc Drugs; 2010 Jun 15; 10(1):55-63. PubMed ID: 20104935
    [Abstract] [Full Text] [Related]

  • 11. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun 15; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 12. Aldosterone blockade in heart failure.
    Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 15; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [Abstract] [Full Text] [Related]

  • 13. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F.
    Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668
    [Abstract] [Full Text] [Related]

  • 14. [New evidences on the use of aldosterone receptor antagonists in left ventricular dysfunction: from myocardial infarction to heart failure].
    Greco C, Castelli G, Crea F, Gavazzi A, Gensini GF, Scherillo M, Sinagra G.
    G Ital Cardiol (Rome); 2012 Dec 12; 13(12):809-16. PubMed ID: 23196683
    [Abstract] [Full Text] [Related]

  • 15. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 16. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):425-31. PubMed ID: 16053953
    [Abstract] [Full Text] [Related]

  • 17. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG, Schencking M, Scheer C, Rupp H.
    Praxis (Bern 1994); 1997 Apr 02; 86(14):566-74. PubMed ID: 9198851
    [Abstract] [Full Text] [Related]

  • 18. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F.
    J Am Coll Cardiol; 2011 Nov 01; 58(19):1958-66. PubMed ID: 22032706
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B.
    Circulation; 2005 Mar 08; 111(9):1106-13. PubMed ID: 15723981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.